CS
SYRE icon

Candriam SCA’s Spyre Therapeutics SYRE Stock Holding History

Candriam SCA’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.5M Sell
546,312
-63,970
-10% -$4.67M 0.22% 95
2026
Q1 		$30.8M Buy
610,282
+184,748
+43% +$6.97M 0.16% 137
2025
Q4 		$13.9M Buy
425,534
+21,172
+5% +$553K 0.07% 226
2025
Q3 		$6.78M Buy
404,362
+158,332
+64% +$2.58M 0.04% 323
2025
Q2 		$3.68M Hold
246,030
– – 0.02% 400
2025
Q1 		$3.97M Sell
246,030
-1,561
-0.6% -$32.5K 0.02% 378
2024
Q4 		$5.76M Buy
247,591
+142,591
+136% +$4.18M 0.03% 335
2024
Q3 		$3.09M Hold
105,000
– – 0.02% 435
2024
Q2 		$2.47M Hold
105,000
– – 0.02% 453
2024
Q1 		$3.98M Buy
+105,000
New +$3.04M 0.03% 383

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Candriam SCA's SYRE Position: Q2 2026 in Review

Candriam SCA reduced its Spyre Therapeutics (SYRE) stake by 10% in Q2 2026, selling an estimated $4.67M and leaving 546,312 shares worth $48.5M. The position accounts for 0.22% of the portfolio, ranked #95.

Candriam SCA first reported a position in SYRE in Q1 2024 and has held it in 10 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Candriam SCA held 546,312 shares of Spyre Therapeutics worth $48.5M as of Q2 2026.
  • Candriam SCA sold 63,970 Spyre Therapeutics shares in Q2 2026, an estimated $4.67M.
  • Spyre Therapeutics made up 0.22% of Candriam SCA's portfolio in Q2 2026, its #95 holding.
  • Candriam SCA first reported a position in Spyre Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.